Resveratrol (SRT501) Increases Apoptosis of Liver Metastasis in Patients with Colorectal Cancer

SRT501 is a micronized formulation of resveratrol that has significantly increased oral bioavailability. In this study, patients with colorectal cancer and hepatic metastases scheduled to undergo hepatectomy were given SRT501 prior to surgery. Examination of surgically removed tissues showed a 39% increase in apoptosis (programmed cell death) in the patient’s malignant hepatic tissue compared with tissue from the placebo-treated patients. I like this approach because is addresses the issue of bioavailability and provides further evidence of the benefits of nutraceuticals for adjunct therapy.
Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases – Safety, Pharmacokinetics, and Pharmacodynamics.

Speak Your Mind